Antihypertensive drugs are not harmful in patients with COVID- 19
DOI:
https://doi.org/10.19230/jonnpr.3742Keywords:
COVID-19, pandemic, Antihypertensive drugsAbstract
-
Downloads
References
Gallo R, Montagnier L. The discovery of HIV as the cause of AIDS. N Engl J Med. (2003) 349:2283–5. doi: 10.1056/NEJMp038194
John A. Jarcho, Julie R. Ingelfinger, Mary Beth Hamel, Ralph B. D’Agostino, Sr., David P. Harrington. Inhibitors of the Renin–Angiotensin–Aldosterone System and COVID-19. New Engl J Med. May 1, 2020 DOI: 10.1056/NEJMe2012924
Kendrick M. Perhaps 4X more likely to die of COVID-19 if take ACE inhibitors (reduce blood pressure). VitaminDWiki. March 22, 2020 (https://vitamindwiki.com/Perhaps+4X+more+likely+to+die+of+COVID-19+if+take+ACE+inhibitors+%28reduce+blood+pressure%29+-+March+2020. ).
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of COVID-19. N Engl J Med. DOI: 10.1056/NEJMoa2006923.
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID- 19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.
Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of COVID- 19. N Engl J Med. DOI: 10.1056/NEJMoa2008975.
Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020;9:757-760.
Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020 April 17 (Epub ahead of print).
Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 2020 April 23 (Epub ahead of print).
Bean DM, Kraljevic Z, Searle T, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-COVID-19 infection in a multi-site UK acute hospital trust. MedRxiv. 2020 (https://www.medrxiv.org/content/10.1101/2020.04.07.20056788v1.opens in new tab) (preprint).
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
